Cargando…

帕博利珠单抗联合安罗替尼四线治疗EGFR基因敏感突变阳性肺腺癌1例

45.7% of Chinese patients with advanced lung adenocarcinoma were reported to harbour sensitizing epidermal growth factor receptor (EGFR) mutations. Limited therapeutic options are left for non-small cell lung cancer (NSCLC) harbouring sensitizing EGFR mutations after failure of EGFR-tyrosine kinase...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560986/
https://www.ncbi.nlm.nih.gov/pubmed/34628779
http://dx.doi.org/10.3779/j.issn.1009-3419.2021.102.25